Biogen says it received a subpoena from the feds in December relating to rebate payments and Biogen's co-pay assistance programs for Tecfidera and other…

It’s official: Amgen’s PCSK9 drug Repatha cut heart risks in an outcomes trial. But with details still secret, it's unclear whether the data can turn…

Novo Nordisk was already worried about the U.S., what with stepped-up competition from new rivals and hardball pricing tactics by payers. But it’s even more…

In the face of public backlash, Merck & Co. has now offered up a report card that shows its list price hikes in the U.S. exceeded 10% only once in recent…

BMS cut its 2017 guidance, but its I-O franchise remains strong—and one analyst suggests setbacks plus value could tag the company as a takeover target.

High drug prices may be the key topic of conversation in the industry but you wouldn’t know it from Novartis, where pressure on prices contributed to slower…

Kaléo Pharma’s expensive Auvi-Q has hit resistance from some of the nation’s top pharmacy benefit managers and insurers.

Merck will pony up $625 million plus royalties on its blockbuster cancer med Keytruda to settle up its patent dispute with Opdivo-maker Bristol-Myers. The…

Eli Lilly was so optimistic about its experimental Alzheimer’s treatment, solanezumab, the company staffed up in anticipation of its approval—a move that has…

Corporate